Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 6
Submit an article Journal homepage
43
Views
9
CrossRef citations to date
0
Altmetric
Review

An emerging role for calcium sensitisation in the treatment of heart failure

Leif Erhardt Lund University, Malmö University Hospital, 205 02 Malmö, Sweden. [email protected]
Pages 659-670 | Published online: 11 Jul 2005

Bibliography

  • CLELAND JGF, KHAND A, CLARK A: The heart failure epidemic: exactly how big is it? Eur. Heart' (2001) 22:623–626.
  • LLOYD-JONES D, LARSON M, LEIP E et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 106:3068–3072.
  • •This landmark analysis supports the epidemic emergence of congestive heart failure (CHF) in the US. Based on 8000 subjects who were free of CHF at baseline, the study determined that the lifetime risk for CHF is one in five for both men and women.
  • BLEUMINK G, KNETSCH A, STURKENBOOM M et al.: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. Eur. Heart' (2004) 25:1614–1619.
  • •In this European prospective, population-based cohort study, nearly 8000 participants ( 55 years of age) were included. Findings indicate that the prevalence of heart failure is high; lifetime risk was 33% for men and 29% for women at 55 years of age. Only 35% of people with heart failure are expected to survive 5 years after diagnosis.
  • STEWART S, MacINTYRE K, CAPEWELL S, McMURRAY J: Heart failure and the aging population: an increasing burden in the 21st century? Heart (2003) 89:49–53.
  • STEWART S, MacINTYRE K, HOLE D, CAPEWELL S, McMURRAY J: More 'malignant' than cancer? Five year survival following a first admission for heart failure. Eur .1 Heart Failure (2001) 3:315–322.
  • DOGGRELL S, BROWN L: Present and future pharmacotherapy for heart failure. Expert Opin. Pharmacother. (2002) 3:915–930.
  • JAAGOSILD P, DAWSON N, THOMAS C et al.: Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. Arch. Intern. Med. (1998) 158:1081–1089.
  • HUNTS, BAKER D, CHIN M et al.: ACC/AHA Guidelines for the evaluation and treatment of chronic heart failure in the adult: executive summary. Circulation (2001) 104:2996–3007.
  • CLELEND J, DARGIE H, DREXLER H et al.: Guidelines for the diagnosis and treatment of chronic heart failure. Update of the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur. Heart J. (2005) (In Press).
  • TASK FORCE ON ACUTE HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur. Heart J. (2005) 26:384–416.
  • ••Newly updated for 2005, this publicationfrom the European Society of Cardiology clearly defines acute heart failure and provides evidence-based guidelines for diagnosis and treatment.
  • RADOVANCEVIC B, VRTOVEC B, FRAZIER 0: Left ventricular assist devices: an alternative to medical therapy for end-stage heart failure. Curr. Opia Cardiol. (2003) 18:210–214.
  • VITALI E, COLOMBO T, FRATTO P et al.: Surgical therapy in advanced heart failure. Am. J. Cardiol. (2003) 91:88F–94F.
  • TANEJA T, JOHNSON MR, GHEORGHIADE M: Current status of acute intravenous therapy for chronic heart failure exacerbations. Congestive Heart Failure (1999) 5:199–207.
  • FELKER G, O'CONNER C: Inotropic therapy for heart failure: an evidence-based approach. Am. Heart J. (2001) 142:393–401.
  • THACKRAY S, EASTHAUGH J, FREEMANTLE N, CLELAND J: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur .1 Heart Failure (2002) 4:515–529.
  • HAIKALA H, POLLESELLO P: Calcium sensitivity enhancers. 'Drugs 2000(2000) 3:1199–1205.
  • CUFFE M, CALIFF R, ADAMS K et al.:Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA (2002) 287:1541–1547.
  • •An important prospective study (n = 949). Results from this trial show that milrinone does not provide long-term outcome benefits for patients with exacerbation of heart failure.
  • SCHWARTE L, PICKER 0, BORNSTEIN S, FOURNELL A, SCHEEREN T: Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Grit. Care Med. (2005) 33:135–142.
  • USTA C, PUDDU P, PAPALIA U et al: Comparison of inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae. Cardiovasc. Pharmacol. (2004) 44:622–625.
  • ERHARDT L: Is calcium sensitisation the best strategy to improve myocardial contractility in acute heart failure? Ital. Heart J. (2003) 4\(Suppl. 2):275–335.
  • LEHMANN A, BOLDT J, KIRCHNER J: The role of Ca2' sensitizers for the treatment of heart failure. Curr. Opin. Grit. Care (2003) 9:337–344.
  • CLELAND JG, NITIKIN N, McGOWAN J: Levosimendan: the first in a new class of inodilator for acute and severe heart failure. Expert Rev Cardiovasc. Ther. (2004) 2:9–19.
  • FUENTES V: Use of pimobendan in the management of heart failure. Vet Clinics Am. Small AlliM. Pract. (2004) 34:1145–1155.
  • BERS D: Calcium fluxes involved in control of cardiac myocyte contraction. Circ. Res. (2000) 87:275–281.
  • ARTEAGA G, KOBAYASHI T, SOLARO R: Molecular actions of drugs that sensitize cardiac myofilaments to Ca2'. Ann. Med. (2002) 34:248–258.
  • ENDOH M: Mechanisms of action of novel cardiotonic agents. I Cardiovasc. Pharmacol. (2002) 40:323–338.
  • NIELSEN-KUDSK J, ALDERSHVILE J: Will calcium sensitizers play a role in the treatment of heart failure?' Cardiovasc. Pharmacol. (1995) 26:S77–S84.
  • TERAMURA S, YAMAKADO T: Calcium sensitizers in chronic heart failure: inotropic interventions-reservation to preservation. Cardiologia (1998) 43(4):375–385.
  • SORSA T, POLLESELLO P, PERMI P, DRAKENBERG T, KILPELAINEN I: Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. I Mol. Cell. Cardiol. (2003) 35:1055–1061.
  • ROSEVEAR P, FINLEY N: Molecular mechanism of levosimendan: an update. Molec. Cell Cardiol. (2003) 35:1011–1015.
  • PAPP Z, VAN DER VELDEN J, BORBELY A, EDES I, STEINEN G: Effects of Ca2' -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts. J. Muscle Res. Cell Moth. (2004) 25:219–224.
  • FUJINO K, SPERELAKIS N, SOLARO R: Sensitization of dog and guinea pig heart myofilaments to Ca2' activation and the inotropic effect of pimobendan: comparison with milrinone. Circ. Res. (1988) 63:911–922.
  • SCHELD H, FRITSCHE R, SCHLEPPER M, VAN MEEL J: Pimobendan increases calcium sensitivity of skinned human papillary muscle fibers. Pharmacol. (1989) 29:360–366.
  • THE EPOCH STUDY GROUP: Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure. Cirri. (2002) 66:149–157.
  • BOHM M, MORANO I, PIESKE B et al.: Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ. Res. (1991) 68:689–701.
  • LUBSEN J, JUST H, HJALMARSSON A et al.: Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart (1996) 76:223–231.
  • •Results of the PICO trial (n = 317) reveal an important shortfall regarding the use of pimobendan. Despite pimobendan's benefits for improving exercise capacity in patients with chronic heart failure, the hazard of mortality was nearly twofold higher in pimobendan-treated groups than in the placebo group.
  • KITADA Y, KOBAYASHI T, NARIMATSU A, OHIZUMI Y: Potent stimulation of myofilament force and adenosine triphosphatase activity of canine cardiac muscle through a direct enhancement of troponin C Ca2' binding by MCI-154, a novel cardiotonic agent. Pharmacol. Exp. Ther. (1989) 250:272–277.
  • BETHKE T, MEYER W, SCHMITZ W et al.: High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium. 1 Cardiovasc. Pharmacol (1993) 21:847–855.
  • BRIXIUS K, MEHLHORN U, BLOCH W, SCHWINGER H: Different effect of the Ca2' sensitizers EMD-57033 and CGP-48506 on cross-bridge cycling in human myocardium. ./. Pharmacol Exp. Ther. (2000) 295:1284–1290.
  • PAN B-S, JOHNSON R: Interaction of cardiotonic thiadiazinon derivatives with cardiac troponin C. J. Biol. Chem. (1996) 271:817–823.
  • KIVIKKO M, ANTILA S, EHA J, LEHTONEN L, PENTIKAINEN P: Pharmacodynamics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int .1 Pharmacol Ther. (2002) 40:465–471.
  • KIVIKKO M, ANTILA S, EHA J, LEHTONEN L, PENTIKAINEN P: Pharmacodynamics and safety of a new calcium sensitiser, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J. Clia Pharmacol (2002) 42:43–51.
  • EDES I, KISS E, KITADA Y et al: Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2' sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ. Res. (1995) 77:107–113.
  • HAIKALA H, NISSINEN E, ETEMADZADEH E, LEVIJOKI J, LINDEN I-B: Troponin-C mediated calcium sensitization induced by levosimendan does not impair relaxation. Cardiovasc. Pharmacol (1995) 25:794–801.
  • SZILAGYI S, POLLESELLO P, LEVIJOKI J et al.: The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur.j Pharmacol. (2004) 486:67–74.
  • LANCASTER M, COOKS: The effects oflevosimendan on [Ca21 in guinea-pig isolated ventricular myocytes. Eur. Pharmacol (1997) 339:97–100.
  • HASENFUSS G, PIESKE B, CASTELL M et al.: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation (1998) 98(20):2141–2147.
  • JANSSEN PML, DATZ N, ZEITZ 0, HASENFUSS G: Levosimendan improves diastolic and systolic function in failing human myocardium. Eur. Pharmacol (2000) 404:191–199.
  • BRIXIUS K, REICKE S, SCHWINGER R: Beneficial effects of the Ca(2÷) sensitizer levosimendan in human myocardium. Am. J. Physic] Heart Circ. Physiol (2002) 282:H131–H137.
  • HAIKALA H, KAIVOLA J, NISSINEN Eet al.: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. Mol. Cell. Cardiol (1995) 27:1859–1866.
  • HAIKALA H, LINDEN I-B: Mechanisms of action of calcium sensitizing drugs. Cardiovasc. Pharmacol (1995) 26:S10–S19.
  • MEBAZAA A, ERHARDT L: Levosimendan: a new dual-action drug for treatment of acute heart failure. Int. J. Clim Pract. (2003) 57:410–416.
  • NG T: Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy (2004) 24:1366–1384.
  • YOKOSHIKI H, KATSUBE Y, SUNAGAWA M et al: Levosimendan, a novel Ca2' sensitizer, activates the glibenclamide-sensitive K.* channel in rat arterial myocytes. Eur. Pharmacol (1997) 333:249–259.
  • PATARICZA J, HOHN J, PETRI A, BALOGH A, PAPP J: Comparison of the vasorelaxing effect of cromakalim and the new inodilator levosimendan in human isolated portal vein. Pharm. Pharmacol (2000) 52:213–217.
  • KAHEINEN P, POLLESELLO P, LEVIJOKI J, HAIKALA H: Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J. Cardiovasc. Pharmacol (2001) 37:367–374.
  • POLLESELLO P, MEBAZAA A: ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr. °pia Crit. Care (2004) 10:436–441.
  • LILLEBERG J, NIEMINEN M, AKKILA J et al.: Effects of a new calcium sensitiser, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilisation early after coronary artery bypass grafting. Eur. Heart J. (1998) 19:660–668.
  • BOWMAN P, HAIKALA H, PAUL RJ: Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. I Pharmacol Exp. Ther. (1999) 288(1):316–325.
  • PAGEL P, HETTRICK D, WARLTIER D: Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br. J. Pharmacol (1996) 119:609–615.
  • DUTOIT E, HOFMANN D, McCARTHY J, PINEDA C: Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligations and reperfusion in the in vivo pig model. Heart (2001) 86:81–87.
  • DUTOIT E, MULLER C, McCARTHY J,OPIE L: Levosimendan: effects of a calcium sensitizer on function and arrythmias and cyclic nucleotide levels during ischemia/ reperfusion in the Landendorff-perfused guinea pig heart. J. Pharmacol Exp. Ther. (1999) 290:505–514.
  • KERSTEN JR, MONTGOMERY MW, PAGEL PS, WARLTIER D: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth. Arralg. (2000) 90:5–11.
  • JAMALI IN, KERSTEN JR, PAGEL PS, HETTRICK D, WARLTIER D: Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth. Arralg. (1997) 85:23–29.
  • TACHIBANA H, CHENG H, UKAI T et al.: Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am. J. Physiol Heart Circ Physiol (2005) 288:H914–922.
  • KOPUSTINSKIENE D, POLLESELLO P, SARIS N-E: Potassium-specific effects of levosimendan on heart mitochondria. Biochem. Pharmacol (2004) 68:807–812.
  • ERIKSSON 0, POLLESELLO P, HAIKALA H: Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. Cardiovasc. Pharmacol (2004) 44:316–321.
  • KAHEINEN P, POLLESELLO P, LEVIJOKI J, HAIKALA H: Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. 1. Cardiovasc. Pharmacol (2004) 43:555–561.
  • UKKONEN H, SARASTE M, AKKILA J, KNUUTI J: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin. Pharmacol. Ther. (2000) 68:522–531.
  • LEVIJOKI J, POLLESELLO P, KAHEINEN P, HAIKALA H: Improved survival with simendan after experimental myocardial infarction in rats. Eur. Pharmacol. (2001) 419:243–248.
  • LEPRAN I, PAPP J: Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coraonary artery occlusion in conscious rats. Eur. Pharmacol. (2003) 19:171–176.
  • MOISEYEV V, PODER P, ANDREJEVS N et al: RUSSLAN STUDY INVESTIGATORS: Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction (a randomised, placebo-controlled, double-blind study; RUSSLAN). Eur. Heart J. (2002) 23:1422–1432.
  • ••This key study demonstrates the benefitsof levosimendan in patients with acute heart failure (n = 504) following myocardial infarction. Results strongly support the safety of levosimendan and also demonstrate a reduction in short-term mortality that appears to be sustained over the longer term.
  • SLAWSKY MT, COLUCCI WS, GOTTLIEB SS: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation (2000) 102:2222–2227.
  • FOLLATH F, CLELAND J, JUST H et al: Efficacy and safety of intravenous levosimendan, a novel calcium sensitiser, in severe low output failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360:196–202.
  • ••This important study establishes thebenefits of levosimendan compared with dobutamine in patients with exacerbation of chronic heart failure (n = 203). Results showed superior haemodynamic effects with levosimendan, and a trend toward Unproved symptoms. There was also a significant reduction in short-term mortality, a benefit that was sustained for up to 6 months.
  • CLELAND J, GHOSH J, FREEMANTLE N et al: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCG, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronization therapy in heart failure. Eur. I Heart Failure (2004) 6:501–508.
  • KIVIKKO M, LEHTONEN L, COLUCCI WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation (2003) 2003:81–86.
  • ZAIRIS M: The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: CAlcium Sensitizer or Inotrope or NOne in low output heart failure (CASINO) study. J. Am. Coll Cardiol. (2004) 43:206A.
  • PACKER M, COLUCCI W, FISHER L et al.: Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. I Card. Fad. (2003) 9(S61):219A.
  • BARISIN S, HUSEDZINOVIC I, SONICKI Z et al: Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. I Cardiothorac Pharmacol (2004) 44:703–708.
  • NIJHAWAN N, NICOLOSI AC, MONTGOMERY MW et al: Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. ./. Cardiovasc. Pharmacol. (1999) 34(2):219–228.
  • NOTO A, GIACOMINI M, PALANDI A et al: Levosimendan in septic cardiac failure. Intensive Care Med. (2005) 31:164–165.
  • OLDNER A, KONRAD D, WEITZBERG E et al.: Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Grit. Care Med. (2001) A29:2185–2193.
  • SONNTAG S, SUNDBERG S, LEHTONEN L, KLEBER F: The calcium sensitizer levosimendan improves function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. I Am. Coll. Cardiol. (2004) 43:2177–2182.
  • LEHMANN A, LANG J, BOLDT J, ISGRO F, KIESSLING A: Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med. ScL Monk (2004) 10:MT89-MT93.
  • MEBAZAA A, KARPATI P, RENAUD E, ALGOTSSON L: Acute right ventricular failure-from pathophysiology to new treatments. Intensive Care Med. (2004) 30:185–196.
  • BRAUN J, SCHNEIDER M, DOHMEN P, DOPFMER U: Successful treatment of dilatative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support. Cardiothorac. Vasc. Anesth. (2004) 18:772–774.
  • BENLOLO S, LEFOLL C, KATCHATOURYAN V, PAYEN D, MEBAZAA A: Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth. Analg. (2004) 98:822–824.
  • SCHULZE-NEICK I, LUTHER Y, EWERT P, LEHMKUHL H, HETZER R: End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation. Transplantation (2004) 78:1237–1238.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.